Status:
UNKNOWN
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-90 years
Brief Summary
The determination of the 2D6 genotype will enable us to determine the way flecainide is metabolized by the liver. Some individuals are poor metabolizers and some individuals are extensive metabolizers...
Detailed Description
Pharmacogenetics is the study of genetic variations on drug metabolizing enzymes and transporters. Pharmacogenetics is one of the first clinical applications of the Human Genome Project. Pharmacogenom...
Eligibility Criteria
Inclusion
- Patients with recurrent AF
- Patients with a structurally normal heart
- Patients \> 18 YO
- Patients who signed an informed consent
Exclusion
- Renal failure with creatinine clearance less than 40
- Elevated liver enzymes 3 times the normal range, or causing coagulation test abnormality
- Pregnant patients
- Patients treated with psychiatric agents
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00945867
Start Date
September 1 2009
End Date
August 1 2010
Last Update
April 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofeh Medical Center
Zrifin, Israel, 00000